Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
ArriVent BioPharma, Inc. (AVBP) had Cash Flow from Financial Activities of $140.96M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-49.89M |
|
-- |
|
-- |
|
$52.69M |
|
$-52.69M |
|
$2.80M |
|
$-49.89M |
|
$-49.89M |
|
$-49.89M |
|
$-49.89M |
|
$-49.89M |
|
$-49.89M |
|
$-52.69M |
|
$-53.21M |
|
47.61M |
|
47.61M |
|
$-1.05 |
|
$-1.05 |
|
| Balance Sheet Financials | |
$394.17M |
|
-- |
|
$0.55M |
|
$394.72M |
|
$27.84M |
|
-- |
|
$0.03M |
|
$27.88M |
|
$366.84M |
|
$366.84M |
|
$366.84M |
|
48.32M |
|
| Cash Flow Statement Financials | |
$-81.47M |
|
$49.65M |
|
|
Cash Flow from Financial Activities |
$140.96M |
$45.54M |
|
$154.68M |
|
$109.14M |
|
$12.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-81.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.60% |
|
-13.60% |
|
-12.64% |
|
-13.60% |
|
$7.59 |
|
$-1.71 |
|
$-1.71 |
|